Altria Group -- How the Business Works
Altria Group is the dominant US tobacco company, generating $23.3B in FY2025 revenue almost
entirely from domestic operations. The business is built on Marlboro -- the single most
powerful cigarette brand in America with ~40% retail share -- plus a portfolio of smokeless
tobacco (Copenhagen, Skoal), oral nicotine pouches (on!), and a sidelined e-vapor platform
(NJOY). Approximately 88% of revenue comes from combustible cigarettes, a category declining
8-10% annually in volume but supported by extraordinary oligopoly pricing power (8.4% net
price realization in FY2025). Smokable adjusted OCI margins reached 63.4% -- world-class for
any consumer staples business. The strategic pivot to smoke-free products centers on on! oral
nicotine pouches (competing with Philip Morris ZYN) and the stalled NJOY e-vapor platform
(ACE device banned by ITC in March 2025, $1.3B impairment). Altria also holds a 10% stake in
AB InBev (BUD). The 6.45% dividend yield (60 consecutive years of increases) provides income
support, while ESG/institutional exclusion creates a structural valuation gap. Calendar fiscal
year. Composite score 5.5/10 (AVOID / borderline watchlist).
Price / Composite Score
$65.76 / 5.5
AVOID -- borderline watchlist
US Cigarette Retail Share
~45%
Marlboro ~40% alone | #1 by 2x
Smokable OCI Margin
63.4%
FY2025 | +1.8pp YoY
Dividend Yield
6.45%
60 consecutive years of increases
How Altria makes money -- cigarettes fund everything else
Revenue by Product Segment (FY2025)
Smokable Products
$20.5B (~88%)
Marlboro, Basic, other cigarettes | Middleton cigars
Volume -9.5% YoY but net price realization +8.4% | OCI margin 63.4%
Oral Tobacco
$2.8B (~12%)
Copenhagen, Skoal (MST) + on! pouches
on! share 7.7% of total oral | MST declining, pouches growing
E-Vapor
~$21M
NJOY (ACE banned)
<1% of revenue | $1.3B impairment in Q4 2025
Value Chain -- From Tobacco Leaf to Consumer
Tobacco Procurement
Domestic + imported leaf; KT&G partnership
→
Manufacturing
PM USA, USSTC, Helix (on!)
→
Distribution
350K+ US retail locations
→
Consumer
C-stores, gas stations, tobacco shops
Brand Portfolio -- Four Nicotine Platforms
Cigarettes (Cash Cow)
Marlboro (~40% share), Basic (discount defense)
88% of revenue | 63.4% OCI margin | declining volumes
Smokeless Tobacco
Copenhagen, Skoal -- moist smokeless tobacco (MST)
Mature / declining as pouches cannibalize | stable margins
Oral Nicotine (on!)
on! pouches + on! PLUS (launched Dec 2025)
Fastest-growing category (+45% YoY) but distant #2 to ZYN
E-Vapor (NJOY)
NJOY ACE banned (ITC patent ruling, Mar 2025)
Effectively zero revenue | $1.3B impaired | no 2026 return
Pricing power is the engine; volume decline is the constraint.
Altria generated 8.4% net price realization in FY2025 even as cigarette volumes fell
~10%. This is possible because the US cigarette market is a textbook oligopoly -- Altria
(~45% share) and Reynolds American (~25-27%) together control over 70% of the market.
Excise taxes, regulatory barriers, and marketing restrictions make new entry virtually
impossible. The result is 63%+ OCI margins on a declining volume base. The critical
question is whether the smoke-free pivot (on!, NJOY) can build a second growth engine
before cigarette volumes erode too far.
Revenue and volume data from Altria FY2025 earnings release via Daloopa. Calendar fiscal year (Dec FYE).
Competitive position -- US cigarette oligopoly
US Cigarette Market Share (Oligopoly Gate: PASS -- but secularly declining category)
| Company | Retail Share | Key Brands | Assessment |
|---|---|---|---|
| Altria (PM USA) | ~45% | Marlboro (~40%), Basic (discount) | #1 by 2x | dominant pricing leader |
| Reynolds American (BAT) | ~25-27% | Camel, Newport, Natural American Spirit | #2 -- menthol-heavy portfolio |
| Liggett / Others | ~5-8% | Eagle 20s, deep discount brands | Niche / value segment |
| Deep Discount / Generic | ~20-25% | Fragmented value brands | Growing share as consumers trade down |
Why This Oligopoly Supports Extraordinary Pricing Power
+8.4%
Net Price Realization (FY25)
Offsets -9.5% volume decline
63.4%
Smokable OCI Margin
+1.8pp YoY | world-class
Extreme
Barriers to Entry
FDA, excise tax, marketing ban, distribution
-9.5%
FY25 Volume Decline
vs. historical ~3.3% annual rate
Dominant oligopoly, but in a category declining at 2-3x the historical rate.
The US cigarette market is one of the most concentrated consumer goods markets in the
world. Altria and Reynolds together control ~70%+ of retail sales, and regulatory barriers
(FDA pre-market authorization, marketing restrictions, excise taxes) make new entry nearly
impossible. This supports exceptional pricing power -- Altria grew smokable OCI even as
volumes dropped 10%. However, volume declines have accelerated from the historical ~3.3%
annual rate to 8-10%, driven partly by cross-category migration to illicit flavored
e-vapor. Management sees moderation ahead as FDA enforcement intensifies, but the
structural decline is real. Marlboro slipped below 40% retail share for the first time
in Q4 2025 (39.8%), a psychological milestone.
Market share from Altria earnings releases and Nielsen/MSAI data. Volume decline rates from Altria FY2025 10-K.
Smoke-free pivot -- on! vs. ZYN and the NJOY setback
Oral Nicotine Pouch Market and E-Vapor Status
US Nicotine Pouch Market
+45% YoY
Fastest-growing nicotine category | approaching $5B+
ZYN (Philip Morris): ~66% share | 794M cans shipped in 2025
on! (Altria): ~7.7% share of total oral | ~177M cans | 4.5:1 gap vs. ZYN
NJOY E-Vapor (Sidelined)
$1.3B Impaired
ACE device banned by ITC (Mar 2025) | will NOT return in 2026
$873M goodwill + intangibles write-down in Q4 2025
Modified ACE design completed but pathway to market unclear
on! PLUS -- The Key Catalyst for 2026
FDA Authorized
Marketing granted orders
Regulatory moat vs. illicit competitors
3 States
Launched Dec 2025
National rollout planned H1 2026
Positive
Consumer Feedback
Mouthfeel / comfort differentiation
Unproven
Scale Execution
Category prices down 12% YoY; on! raised 3%
Altria Total Oral Tobacco Retail Share -- Declining as ZYN Grows the Category
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | Trend |
|---|---|---|---|---|---|---|
| Total Oral Share | 37.8% | -- | -- | -- | 29.6% | -8.2pp -- ZYN diluting share |
| on! Share (Total Oral) | -- | -- | 8.9% | 8.9% | 7.7% | Slipping from peak |
| Marlboro Cig Share | 42.0% | -- | -- | -- | 39.8% | First time below 40% |
The smoke-free transition is positioned in the right categories but losing the share war.
The US nicotine pouch market is growing +45% YoY and approaching $5B+ -- this is
unambiguously the right category to target. But ZYN dominates with ~66% share and shipped
4.5x the cans that on! did in 2025. Altria total oral retail share has collapsed from
37.8% to 29.6% as ZYN growth dilutes Copenhagen/Skoal positioning. on! PLUS (FDA
authorized, national launch H1 2026) is the key swing factor -- positive early consumer
feedback on differentiation, but the product is unproven at scale and competitors are
cutting prices aggressively (-12% YoY). Meanwhile, NJOY e-vapor is effectively a dead
option after the ACE ban and $1.3B impairment. The $2.75B NJOY acquisition has been
largely written down.
Oral nicotine and e-vapor data from Altria Q3/Q4 2025 earnings transcripts and Nielsen/MSAI panel data. ZYN shipment data from Philip Morris International filings.
Adjacent growth -- international optionality and capital return
Emerging Growth Vectors and Capital Allocation
KT&G Partnership
Embryonic
International modern oral + US non-nicotine + manufacturing efficiency
Import/export duty drawback: payback <1 year | new margin lever
International Expansion
Early Stage
Fumi brand: 40,000 retail locations in 7 international markets
Ploom heated tobacco PMTA+MRTPA filed with FDA (Aug 2025)
Capital Return / Dividend
6.45% Yield
60 consecutive years of dividend increases
10% stake in AB InBev (BUD) | Forward P/E 11.7x
Key Monitoring Items for 2026
on! PLUS Launch
National rollout H1 2026
Share trajectory vs. ZYN is THE swing factor
Volume Decline Pace
Improving? Q4 was -7% vs. -11% Q1
Illicit e-vapor enforcement key
Marlboro Share
Sub-40% is a red flag
Watch for stabilization vs. Basic cannibalization
Adjacent growth is optionality, not a near-term earnings driver.
The KT&G partnership, Fumi international expansion, and Ploom heated tobacco are all
years from contributing material revenue. The import/export duty drawback with KT&G
is the most near-term lever (payback under 1 year, visible in H2 2026 financials). The
real near-term story is capital return: a 6.45% dividend yield backed by 60 years of
increases and a forward P/E of 11.7x. ESG/institutional exclusion creates a structural
valuation gap that income investors can exploit -- but this is a managed decline thesis,
not a growth thesis.
KT&G and international data from Altria Q4 2025 earnings transcript. Dividend history from Altria investor relations.
Key risks to the business model
| Risk | Timeframe | Severity | Detail |
|---|---|---|---|
| Accelerating Volume Decline | Ongoing | High | FY25 volumes -9.5% vs. historical ~3.3% annual rate; illicit e-vapor + cross-category migration driving acceleration |
| on! Losing to ZYN | Near-term | High | on! share slipping (7.7% from 8.9% peak); ZYN ships 4.5x the cans; category prices down 12% YoY |
| NJOY Write-Off | Ongoing | Moderate | $2.75B acquisition largely impaired; ACE banned; modified design pathway unclear; no 2026 revenue |
| Marlboro Share Erosion | Ongoing | Moderate | Below 40% for first time (39.8% Q4 2025 vs. 42.0% Q1 2024); Basic discount strategy may cannibalize |
| Regulatory / Litigation | Ongoing | Moderate | Menthol ban withdrawn (positive), but new JUUL litigation adds uncertainty; FDA enforcement unpredictable |
| ESG / Institutional Exclusion | Structural | Low | Creates valuation gap (6.45% yield) but limits shareholder base and multiple expansion potential |
Risk assessment from Altria earnings calls, 10-K filings, and industry research. Share data from Nielsen/MSAI.